393 related articles for article (PubMed ID: 28381462)
1. Renal cell carcinoma: new insights and challenges for a clinician scientist.
Shingarev R; Jaimes EA
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F145-F154. PubMed ID: 28381462
[TBL] [Abstract][Full Text] [Related]
2. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
3. Metastatic renal cell carcinoma: many treatment options, one patient.
Rini BI
J Clin Oncol; 2009 Jul; 27(19):3225-34. PubMed ID: 19470934
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA expression profiling of Xp11 renal cell carcinoma.
Marchionni L; Hayashi M; Guida E; Ooki A; Munari E; Jabboure FJ; Dinalankara W; Raza A; Netto GJ; Hoque MO; Argani P
Hum Pathol; 2017 Sep; 67():18-29. PubMed ID: 28411178
[TBL] [Abstract][Full Text] [Related]
5. Mutations in renal cell carcinoma.
D'Avella C; Abbosh P; Pal SK; Geynisman DM
Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
[TBL] [Abstract][Full Text] [Related]
6. Emerging immunotherapy in advanced renal cell carcinoma.
Mendiratta P; Rini BI; Ornstein MC
Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
[TBL] [Abstract][Full Text] [Related]
7. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Saliby RM; Labaki C; Jammihal TR; Xie W; Sun M; Shah V; Saad E; Kane MH; Kashima S; Sadak K; El Zarif T; Poduval D; Motzer RJ; Powles T; Rini BI; Albiges L; Pal SK; McGregor BA; McKay RR; Signoretti S; Van Allen EM; Shukla SA; Choueiri TK; Braun DA
Cancer Cell; 2024 May; 42(5):732-735. PubMed ID: 38579722
[TBL] [Abstract][Full Text] [Related]
8. [50 years of renal cell carcinoma].
Doehn C
Aktuelle Urol; 2019 Aug; 50(4):378-385. PubMed ID: 31398756
[TBL] [Abstract][Full Text] [Related]
9. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
Singla N; Elias R; Ghandour RA; Freifeld Y; Bowman IA; Rapoport L; Enikeev M; Lohrey J; Woldu SL; Gahan JC; Bagrodia A; Brugarolas J; Hammers HJ; Margulis V
Urol Oncol; 2019 Dec; 37(12):924-931. PubMed ID: 31522865
[TBL] [Abstract][Full Text] [Related]
10. Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
Perego G; Barzaghi P; Vavassori I; Petrelli F
Med Oncol; 2020 Aug; 37(9):81. PubMed ID: 32767163
[TBL] [Abstract][Full Text] [Related]
11. Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma.
Raspollini MR; Montagnani I; Montironi R; Castiglione F; Martignoni G; Cheng L; Lopez-Beltran A
J Clin Pathol; 2018 May; 71(5):467-471. PubMed ID: 29317515
[TBL] [Abstract][Full Text] [Related]
12. New therapeutic developments in renal cell cancer.
Prenen H; Gil T; Awada A
Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
[TBL] [Abstract][Full Text] [Related]
13. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma.
Grünwald V
Oncol Res Treat; 2016; 39(6):353-8. PubMed ID: 27259695
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.
Tripathi A; Lin E; Xie W; Flaifel A; Steinharter JA; Stern Gatof EN; Bouchard G; Fleischer JH; Martinez-Chanza N; Gray C; Mantia C; Thompson L; Wei XX; Giannakis M; McGregor BA; Choueiri TK; Agarwal N; McDermott DF; Signoretti S; Harshman LC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177176
[TBL] [Abstract][Full Text] [Related]
16. Combination immunotherapy in renal cell carcinoma.
Drake CG
Clin Adv Hematol Oncol; 2016 Feb; 14(2):99-100. PubMed ID: 27057808
[No Abstract] [Full Text] [Related]
17. Renal cell carcinoma: current status and future prospects.
Drucker BJ
Cancer Treat Rev; 2005 Nov; 31(7):536-45. PubMed ID: 16236454
[TBL] [Abstract][Full Text] [Related]
18. Importance of Multiparametric Evaluation of Immune-Related T-Cell Markers in Renal-Cell Carcinoma.
Kawashima A; Uemura M; Nonomura N
Clin Genitourin Cancer; 2019 Dec; 17(6):e1147-e1152. PubMed ID: 31473121
[TBL] [Abstract][Full Text] [Related]
19. Complete and Prolonged Response of Renal Cell Carcinoma With Rhabdoid Features to Checkpoint Inhibitor Therapy.
Wynja E; Solomon B; Bleeker J
J Immunother; 2018 Sep; 41(7):340-342. PubMed ID: 29965859
[TBL] [Abstract][Full Text] [Related]
20. From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.
Anker J; Miller J; Taylor N; Kyprianou N; Tsao CK
Cells; 2021 Nov; 10(11):. PubMed ID: 34831452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
